Last reviewed · How we verify
NCT04190472
Intraoperative HPV Testing Evaluation
trial testing IOP HPV test in HSIL, High Grade Squamous Intraepithelial Lesions in 1,553 participants. Status unknown.
1 June 2022
Quick facts
| Lead sponsor | Hospital Universitari Vall d'Hebron Research Institute |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,553 |
| Start date | 1 June 2020 |
| Primary completion | 1 June 2022 |
| Estimated completion | 1 June 2024 |
Drugs / interventions tested
- IOP HPV test
Conditions studied
- HSIL, High Grade Squamous Intraepithelial Lesions — all drugs for HSIL, High Grade Squamous Intraepithelial Lesions →
- Recurrence — all drugs for Recurrence →
Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Who can join
25 and older, female only, with HSIL, High Grade Squamous Intraepithelial Lesions or Recurrence. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
High-grade intraepithelial lesion/cervical intraepithelial neoplasia grade 2-3 is a premalignant cervical lesion caused by persistent high-risk human papillomavirus infection. Human papillomavirus test is a very sensitive risk marker of cervical cancer and it has been incorporated in the follow-up after high-grade intraepithelial lesion treatment. Papillomavirus test performed intraoperatively could be a beneficial approach to anticipate treatment failure, allow for early management and consequently a reduction in costs. The aim of this study is to evaluate if the IOP-HPV test has non-inferior diagnostic utility of HSIL/CIN2-3 recurrence at 24 months as the HPV test performed 6 months after treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04190472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HSIL, High Grade Squamous Intraepithelial Lesions
Currently open trials in the same condition.
- NCT05282095 — Effect of HPV Integration on Prognosis of Young Women With CIN2 in China · recruiting
Other Hospital Universitari Vall d'Hebron Research Institute trials
Trials by the same sponsor.
- NCT07519343 — Migraine and Endometriosis: The FEMININE Study · not yet recruiting
- NCT07509541 — Hemodynamic and Respiratory Instability During Percutaneous Pulmonary Thrombectomy · not yet recruiting
- NCT07456280 — Evaluation of the Non-invasive Electrocardiographic Monitoring Strategy Associated With Early Discharge in Patients With · NA · not yet recruiting
- NCT07281911 — Early Biological and Mechanical Profiling in Sepsis-Associated ARDS · not yet recruiting
- NCT07430501 — Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatme · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04190472 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital Universitari Vall d'Hebron Research Institute
- Last refreshed: 1 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04190472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing